Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Multiple Myeloma
Interventions: Dara-RVd, Tec-RVd; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Aortic Valve Stenosis, Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Ventricular Outflow Obstruction
Interventions: JenaValve Pericardial TAVR System; Device
Lead sponsor: JenaValve Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Sudden Cardiac Death, Arrhythmias, Congestive Heart Failure, Cardiomyopathy
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 1,807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • Columbus, Ohio + 1 more

Conditions: Multiple Myeloma
Interventions: bb2121, Fludarabine, Cyclophosphamide, Lenalidomide; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Preeclampsia, Pregnancy Induced Hypertension
Interventions: Irbesartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 50 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Albuminuria
Interventions: Ramipril + Irbesartan, Ramipril + Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Tustin, California • Miami, Florida • West Palm Beach, Florida + 8 more

Conditions: Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions: Percutaneous mitral valve repair using MitraClip implant; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Evanston, Illinois • Indianapolis, Indiana

Conditions: Cardiovascular Risk Factor, Insulin Resistance, PreDiabetes, Diabetes, Coronary Artery Disease, Hypertension, Prehypertension, Dyslipidemias
Interventions: Use of HealthPals (Telemedicine supported by digital health platform); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Coronary Artery Bypass
Interventions: Atrial Fibrillation; Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Sickle Cell Disease
Interventions: Red Blood Cell, Standard of care; Biological · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 20
States / cities: Tuscaloosa, Alabama • Oakland, California • Washington D.C., District of Columbia + 15 more

Conditions: Pregnancy Related, Cardiovascular Risk Factor, Obesity
Interventions: Stretching Exercise Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Coagulopathy
Interventions: Blood product transfusion based on conventional coagulation tests., Blood product transfusion based on rapid thrombelastography (r-TEG) results.; Biological
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Coronary Artery Disease (CAD)
Interventions: XC001, A195/placebo; Drug
Lead sponsor: XyloCor Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cardiovascular Diseases, Heart Disease Risk Factors
Interventions: Observational Group; Behavioral
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Cancer
Interventions: cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique; Biological · Genetic · Other
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 2,777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more

Conditions: Cardiovascular Risk Factor
Interventions: Multicomponent Virtual Lifestyle Intervention; Behavioral
Lead sponsor: Truemedicine Inc; Other
Eligibility: 30 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atrial Fibrillation
Interventions: Warfarin; Drug
Lead sponsor: Robert Stein; Other
Eligibility: 70 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rockport, Maine

Conditions: Cardiovascular Risk Factor
Interventions: Eggs, Choline Supplement; Other · Dietary Supplement
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Rheumatoid Arthritis, Cardiovascular Diseases
Interventions: celecoxib 200mg capsule, naproxen sodium 550mg tablet, Aspirin 81mg tablet; Drug
Lead sponsor: Platelet and Thrombosis Research, LLC; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Growth & Development, Obesity, Cardiovascular Risk Factor, Metabolic Syndrome, Food Allergy, Cognitive Developmental Delay
Interventions: Infant egg consumption (i.e., age of introduction and frequency of intake); Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 0 Years to 15 Years
Enrollment: 5,374 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Obesity, Diabetes, Cardiovascular Disease
Interventions: Virtual Lifestyle Management; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 62 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Hypertension
Interventions: Nebivolol, atenolol, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertrophic Cardiomyopathy, Coronary Artery Disease
Interventions: Observational: Arrhythmogenic Substrate; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study

Genetic Risk Assessment of Defibrillator Events

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Preeclampsia: A Marker for Future Cardiovascular Risk in Women

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

EVEREST II Pivotal Study High Risk Registry (HRR)

Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology

A Retrospective Analysis of the Predictive Potential of Pre-operative

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

Promoting Stretching Exercise to Reduce Cardiovascular Health Risk in Late Pregnant Women With Obesity

Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

Black Women's Life Experience On Cardiovascular Health Via Ongoing Monitoring

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

Virtual Lifestyle Intervention for Weight Management and Cardiovascular Heal

Anticoagulation Therapy in the Very Old

Assessment of TMAO Formation With Egg Intake Versus Choline Supplement in a Healthy Population

NSAIDs vs. Coxibs in the Presence of Aspirin

Effects of Infant Egg Consumption on Child Health and Cognition Development

Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

Hypertrophic Cardiomyopathy Pilot Study